c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

Abstract excerpt

Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, imatinib, bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class for treatment of selected cancers. A unique member of the RTK family, c-Met, also represents an intriguing target for cancer therapy that is yet to be explored in a clinical setting. The proto-oncogene, c-Met, encodes the high-affinity...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Movement
• Share to Cell Proliferation
• Share to Gene Amplification